Acta Neuropathologica Communications (Feb 2023)

CNS tumor with EP300::BCOR fusion: discussing its prevalence in adult population

  • Arnault Tauziède-Espariat,
  • Emmanuelle Uro-Coste,
  • Philipp Sievers,
  • Yvan Nicaise,
  • Cassandra Mariet,
  • Aurore Siegfried,
  • Gaëlle Pierron,
  • Delphine Guillemot,
  • Joseph Benzakoun,
  • Johan Pallud,
  • Margaux Roques,
  • Fabrice Bonneville,
  • Delphine Larrieu-Ciron,
  • Patrick Chaynes,
  • Raphaël Saffroy,
  • Jocelyne Hamelin,
  • Lauren Hasty,
  • Alice Métais,
  • Fabrice Chrétien,
  • Marcel Kool,
  • Johannes Gojo,
  • Pascale Varlet,
  • RENOCLIP-LOC

DOI
https://doi.org/10.1186/s40478-023-01523-y
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 7

Abstract

Read online

Abstract The Central Nervous System (CNS) tumor with BCOR internal tandem duplication (ITD) has recently been added as a novel embryonal histomolecular tumor type to the 2021 World Health Organization (WHO) Classification of CNS Tumors. In addition, other CNS tumors harboring a BCOR/BCORL1 fusion, which are defined by a distinct DNA-methylation profile, have been recently identified in the literature but clinical, radiological and histopathological data remain scarce. Herein, we present two adult cases of CNS tumors with EP300::BCOR fusion. These two cases presented radiological, histopathological, and immunohistochemical homologies with CNS tumors having BCOR ITD in children. To compare these tumors with different BCOR alterations, we performed a literature review with a meta-analysis. CNS tumors with EP300::BCOR fusion seem to be distinct from their BCOR ITD counterparts in terms of age, location, progression-free survival, tumor growth pattern, and immunopositivity for the BCOR protein. CNS tumors from the EP300::BCOR fusion methylation class in adults may be added to the future WHO classification.

Keywords